Background previous studies have suggested that the activity of enzymes involved in the urea cycle may modulate nitric oxide (NO) production, arterial vasomotion, and hypertension. Our aim was to determine whether hypertension and coronary vasomotion could be associated with polymorphisms within the ornithine transcarbamylase (OTC) gene, located on chromosome X and coding for a key-enzyme of the urea cycle.
Methods
Among 11 OTC polymorphisms that were originally selected from databases, the tag single-nucleotide polymorphism (sNp) rs5963409 and the independent sNp rs1800321 were tested for association with hypertension in two independent population samples recruited in Northern (Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) study, n = 1,138) and Western (Etude du Vieillissement Artériel (EVA) study, n = 1,166) France. the vasomotor response of coronary arteries to methylergonovine maleate and isosorbide dinitrate was also evaluated in an independent sample (the vasomotion study, n = 121).
results
In males, the frequency of the rs5963409 minor allele was consistently higher in hypertensive (Ht) than in normotensive subjects in the MONICA and EVA studies. In the combined sample, the rs5963409 minor allele was associated with an increased risk of hypertension (odds ratio (OR) (95% confidence interval (CI)) = 1.45 (1.10-1.90); P = 0.008). this association was independent of classical confounding factors. Consistently, rs5963409 minor allele was associated with a greater susceptibility to vasoconstriction in response to methylergonovine maleate (P = 0.0072). In contrast, no significant association between rs5963409 and hypertension could be detected in females.
conclusion
Our results suggest that the OTC rs5963409 polymorphism may be associated with hypertension and coronary vasomotion in males. articles OTC Gene Polymorphisms and Hypertension in urea synthesis, contributes to NO-mediated dilation of coronary arterioles in hypertensive (HT) pigs and to the endothelial dysfunction in salt-induced HT Dahl rats. 12, 13 Finally, expression of the arginosuccinate synthase and arginosuccinate lyase genes, encoding enzymes involved in the biosynthesis of l-arginine, was higher in kidneys of salt-sensitive Dahl rats than in the salt-resistant strain. 14 Therefore, we hypothesized that ornithine transcarbamylase (OTC) might be implicated in BP regulation and human vascular reactivity through its role in urea production and/or its potential impact on NO bioavailability.
OTC is encoded by a gene located on the X chromosome. In order to test the potential involvement of OTC in BP regulation, we performed an association study of OTC gene (OTC) polymorphisms with hypertension in two different French samples (n = 1,138 and n = 1,166) and with coronary vasomotion in an independent sample of 121 patients.
Methods
The MONICA and EVA studies. Association between OTC gene polymorphisms and hypertension was assessed in two independent French population samples, characteristics of which have been described elsewhere. 15, 16 Briefly, the Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) study was recruited in 1995-1996, in the urban community of Lille (Northern France) within the framework of the World Health Organization-MONICA project. 15 The population was composed of 1,195 Caucasian subjects, aged 35-64 years, randomly selected from the electoral rolls. The Etude du Vieillissement Artériel (EVA) study was composed of Caucasian subjects living in Nantes (Western France). 16 Between 1991 and 1993, volunteers aged 59-71 years were selected from electoral rolls. Among these, 1,273 subjects were followed up for 2 years.
In both populations, information was collected using a standardized questionnaire, which provided data about personal habits, medical history, and drug treatment. A blood sample was collected for all subjects. Anthropometric characteristics were recorded and a set of biological variables was determined in fasting blood samples. Systolic (SBP) and diastolic (DBP) BP were measured twice with an interval of at least 5 min, in sitting position, after at least a 5-10 min rest. A mercury sphygmomanometer and a digital electronic tensiometer (SP9; Spengler, Antony, France) were used in the MONICA study and in the EVA study, respectively. For each study, the mean of the two independent measurements was used for statistical analyses. Subjects were classified as nonsmokers and current or former smokers. Diabetes was defined by the use of antidiabetic drugs and/or a fasting plasma glucose level ≥7 mmol/l. Hypertension was defined as an SBP of at least 140 mm Hg and/or a DBP of at least 90 mm Hg, or the current use of antihypertensive medication. Phenotypic and genetic variables were available for 1,138 subjects (573 males and 565 females) from the MONICA study, and for 1166 subjects (484 males and 682 females) from the EVA study. The general characteristics of these two independent samples are shown in Table 1 .
The vasomotion study. The study protocol was detailed previously. 17 Briefly, 140 Caucasian patients with an angiographically normal coronary tree were consecutively recruited. The vasomotor responses of normal coronary arteries to methylergonovine maleate, a potent vasoconstrictor, and to isosorbide dinitrate (ISDN), an endothelium-independent dilator, were evaluated in these patients. All drugs were discontinued 48 h before angiography and vasomotor responses were evaluated as follows: (i) methylergonovine maleate (100 µg) was injected intravenously and an angiogram was recorded 3 min later, (ii) an additional dose of methylergonovine maleate (300 µg) was injected, and another angiogram was recorded 3 min later, (iii) 200 µg of ISDN was injected into the coronary artery and another angiogram was obtained 2 min later, (iv) 2 mg of ISDN was injected and a final angiogram was recorded 2 min later. All coronary angiograms were analyzed with the computer-assisted evaluation of stenosis and restenosis system as described elsewhere. 17 Maximal response to methylergonovine maleate and ISDN was expressed relative to baseline diameter according to the formula: Maximal constriction by 300 µg of methylergonovine maleate = ((diameter after methylergonovine − baseline diameter)/baseline diameter) × 100 (%), and Maximal dilatation by 2 mg of ISDN = ((diameter after ISDN − baseline diameter)/baseline diameter) × 100 (%). The vasomotion study sample was composed of 121 subjects with fully available phenotypic and genetic data. Main characteristics of this sample are reported in Table 1 .
Study protocols were approved by the local ethics committees and written informed consent was obtained from all participants.
SNP selection and genotyping. A total of 11 single-nucleotide polymorphisms (SNPs) were selected from the NCBI/SNP database (http://www.ncbi.nlm.nih.gov/SNP) and from the literature 18 based on their location and/or putative functionality (see Supplementary Table S1 online). Genotyping was performed by the restriction-fragment length polymorphism method for 10 SNPs. The rs57752938 SNP was characterized by electrophoresis on 8% acrylamide gels after PCR. Ten percent of the genotypes were randomly double-checked and no discrepancy was found.
Statistical analysis. The OTC gene being located on chromosome X, analyses were performed in males and females separately. The pairwise linkage disequilibrium (LD) between the OTC polymorphisms was computed using standard formulas of r 2 . In hemizygote males, the haplotype frequencies were deduced whereas they were estimated in females using the Thesias software. 19 Differences between genotype or haplotype groups were assessed by χ 2 , analysis of variance or analysis of covariance tests, when appropriate. Association with hypertension was first estimated in the MONICA and the EVA studies independently. When the homogeneity of the odds ratio (OR) between the MONICA and the EVA studies was confirmed by the Breslow-Day test, data of both samples were then combined. Associations between the OTC polymorphisms and BP values were evaluated in nontreated subjects only because of the impact of antihypertensive medication on BP values. All tests were adjusted for age, body mass index, diabetes, smoking habits, and cholesterol plasma levels; further adjustment for the study was applied when appropriate.
In the vasomotion study, maximal constriction and maximal vasodilatation mean percentages were compared between genotypes or haplotypes by analysis of variance and analysis of covariance when further adjusted for covariates (i.e. age, family history of coronary artery disease, diabetes, systemic hypertension, and smoking habits). Statistical analyses were carried out using the SAS release 8.2 software (SAS Statistical Institute, Cary, NC). The statistical significance was considered at the 0.05 level.
results selection of relevant snPs for association studies
The 11 OTC SNPs were genotyped in a subgroup of 184 healthy subjects in order to determine allele frequencies (see Supplementary Table S1 online) and pairwise LD. Results enabled to select the most relevant OTC SNPs for association studies. As their minor allele frequency was <5%, the SNPs rs5963029, rs5963412, and rs1800328 were excluded from subsequent analyses. Seven out of the eight remaining SNPs (rs5963408, rs5963409, rs5963410, rs5963411, rs57752938, rs5917572, and rs5917573) were in complete and perfect LD (r 2 = 1), indicating that anyone of these seven SNPs reflects the same haplotype block. Of note, the rs5963409 polymorphism was of particular interest because the corresponding minor allele was shown to abolish the methylation of a CpG island within the promoter. 20 The rs1800321 polymorphism, not fully associated with the haplotype block (r 2 = 0.12), leads to a nonsynonymous substitution (Lys46Arg). Hence, the OTC SNPs selected for the association studies were the rs5963409 and the rs1800321 polymorphisms.
The genotype and allele frequencies obtained in the three population samples are presented in Table 1 . In all samples, genotype distributions for the rs5963409 and rs1800321 polymorphisms were in Hardy-Weinberg equilibrium in females. Because of the chromosome X location, the Hardy-Weinberg hypothesis could not be verified in males due to the absence Comparison of the OTC genotype and haplotype distributions between normotensive and HT males is presented in Table 2 . In the MONICA study, there was a higher prevalence of the rs5963409 minor allele in HT males (P = 0.046).
A similar trend was observed in the EVA study although at borderline significance (P = 0.079). As the Breslow-Day test did not show heterogeneity between samples (χ 2 = 0.01; P = 0.914), the data of the MONICA and the EVA studies were combined. In this combined sample, the rs5963409 minor allele frequency was 31.7% in HT subjects compared to 23.9% in normotensive subjects (P = 0.0048). The rs5963409 polymorphism was associated with a 45% increased risk of hypertension (OR (95% confidence interval (CI)) = 1.45 (1.10-1.90); P = 0.008). Adjustment for confounding factors did not alter this association (OR (95% CI) = 1.42 (1.06-1.90); P = 0.020). On the other hand, the rs1800321 polymorphism was not significantly associated with hypertension. Thus, our results suggested that the significant association of OTC polymorphisms with hypertension was restricted to rs5963409. However, owing to the partial LD between the two studied SNPs (D = −0.06, D′ = |D/D max | = 0.96), we cannot rule out that the impact of rs5963409 could be, at least partly, modulated by the rs1800321 polymorphism. Consequently, in order to define the independent effect of each polymorphism on hypertension, haplotype analyses were performed ( Table 2) . Due to partial LD, only three haplotypes could be observed among the four expected theoretical haplotypes. Indeed, the rs5963409A × rs1800321G haplotype was absent in the MONICA male subjects and was characterized in only two males from the EVA study. Therefore, the haplotype analyses focused on the three remaining frequent haplotypes. These analyses confirmed that the association of OTC polymorphisms with hypertension was restricted to the rs5963409 polymorphism. Indeed, in the combined sample, only the rs5963409A × rs1800321A haplotype was associated with an increased risk of hypertension (OR (95% CI) = 1.45 (1.06-1.99)). The effect was homogeneous between the MONICA and EVA studies (Breslow-Day χ 2 = 1.04, P = 0.599) and was of comparable magnitude with that observed with the rs5963409 polymorphism alone. Conversely, no difference in rs5963409 and rs1800321 genotype distributions between normotensive and HT subjects was observed in females (see Supplementary Table S2 online). Therefore, subsequent analyses were performed only in male subjects. Associations of the OTC polymorphisms with SBP and DBP were tested in nontreated males participating to the MONICA and EVA studies as well as in the 84 males enrolled in the vasomotion study ( Table 3 ). In the EVA and vasomotion studies, the rs5963409 minor allele was associated with increased SBP values (+4.1 mm Hg, P = 0.025, and +16.6 mm Hg, P = 0.012, respectively). On the other hand, the rs1800321 poly morphism was not associated with variations in SBP. Moreover, the haplotype analysis confirmed that the effect was restricted to the rs5963409 polymorphism. In contrast, no difference in SBP was observed in the MONICA study. Regarding DBP, poly morphisms were not associated with any significant variation in all three population samples.
As hypertension is associated with an altered vascular responsiveness to vasoconstrictor and vasodilatator agents, 21, 22 we next evaluated the association between SNP rs5963409 and coronary vasomotion.
association between OTC polymorphism and coronary vasomotion
Proximal and distal baseline segment diameters were similar among rs5963409 and rs1800321 genotypes (data not shown). As expected, proximal and distal segments constricted in response to methylergonovine maleate and relaxed after isosorbide dinitrate ( Table 4) . No association between the rs1800321 polymorphism and abnormal vasomotor response was detected. No difference in vasodilatator responses between rs5963409 minor allele carriers and noncarriers was observed. Conversely, patients carrying the rs5963409 minor allele had a significantly greater maximal vasoconstriction in distal coronary segments than noncarriers (−23.7% vs. −14.3% respectively, P = 0.0087). This enhanced constriction was independent of age, family history of coronary artery disease, diabetes, hypertension, and smoking habits (adjusted P = 0.0072). Finally, haplotype analyses confirmed that the effect on vasomotor response to methylergovine maleate was restricted to the rs5963409 polymorphism. 
discussion
In this work, we report an association of the OTC rs5963409 polymorphism with hypertension and coronary vasomotion, reinforcing the hypothesis of an implication of the urea cycle in BP regulation. The association between rs5963409 and hypertension is highly significant in the combined sample (P = 0.0048) but was at borderline significance in the MONICA (P = 0.046) and EVA samples (P = 0.079). This could be explained by a low statistical power: in the MONICA and EVA samples, the power to detect an OR = 1.5 in males carrying the rs5963409 minor allele was 56 and 52%, respectively, whereas it reached 83% in the combined sample. However, the homogeneity of the data obtained in two independent population samples with different age means, as determined by nonsignificant Breslow-Day tests, reinforces our conclusions regarding a potential impact of OTC gene polymorphisms on hypertension.
In this work, the significant association with hypertension was restricted to males. This sexual difference may be explained, at least in part, by the location of the OTC gene on chromosome X present at a single copy in males. Considering a recessive effect for both studied polymorphisms, this may lead to a lack of statistical power in females. Indeed, the frequency of the rare homozygous genotype in females is low (<10%). Moreover, the etiology and the incidence of hypertension are known to be different between males and females. Accordingly, a sexual dimorphism has been observed for BP in genetically determined hypertension, in humans and animals. 23 Because rs5963409 was associated with hypertension, the effect of this polymorphism on SBP and DBP values was secondarily evaluated. In the EVA and vasomotion studies, our results showed significant increased SBP values in subjects carrying the rs5963409 minor allele. Conversely, we failed to show a significant association of the rs5963409 poly morphism with SBP values in nontreated subjects participating in the MONICA study. This may be related to the fact that, in population-based study, subjects with the highest BP values were prone to drug intervention and consequently excluded from the nontreated subgroup. Accordingly, HT subjects under treatment had higher SBP values than nontreated subjects both in the MONICA (150.6 ± 22.4 mm Hg vs. 133.2 ± 17.0 mm Hg, respectively; P < 0.0001) and EVA (145.8 ± 20.0 vs. 134.8 ± 18.6, respectively; P < 0.0001) studies. On the other hand, the discrepancy regarding the association with BP values may also result from heterogeneity between the different population samples.
In agreement with its deleterious effect on hypertension, the rs5963409 minor allele was associated with an exaggerated constrictor response to methylergonovine maleate. In the vasomotion study, the frequency of the rs5963409 minor allele in males was markedly lower than in the two other population samples. Only subjects with an angiographically normal coronary tree were selected for this study. Therefore, the lower frequency of the rs5963409 minor allele may result from a selection bias. Also, the effect of rs5963409 on coronary vasomotion was observed predominantly in distal coronary segments. This observation was in accordance with previous 24 Of note, our results suggested that the enhanced vasoconstriction associated with the OTC polymorphism might partly account for high BP levels in rs5963409 minor allele carriers. Some previous data suggested an association between gene polymorphisms and both hypertension and coronary vasomotion. For example, the 825C/T polymorphism within the gene encoding the β3-subunit of heterotrimeric G proteins (GNB3) was associated with hypertension 25 and with an enhanced coronary vasoconstriction. 26 The mechanisms whereby OTC may be involved in BP control and arterial vasomotion remain to be elucidated. However, some hypotheses can be made based on the results from the vasomotion study and the pharmacological properties of methylergonovine maleate. Indeed, the pharmacological agents that were used in our study enabled us to investigate the association of OTC genotypes with endothelium-independent vasoreactivity. Methylergonovine maleate presumably has a direct constrictor effect on vascular smooth muscle cells, as it is an agonist of both α-adrenergic and serotoninergic receptors. 27 Its vasoconstrictor action is inhibited by the release of NO from the endothelium. 28 Hence, the association between the OTC gene polymorphism and the increased constrictor response to methylergonovine maleate might be explained by a putative involvement of OTC in vascular smooth muscle reactivity and/or in NO bioavailability. Further investigations are needed to test the validity of these hypotheses.
Of the 11 SNPs selected, only the SNP rs1800321 was referenced in the HapMap database. LD analyses showed that this polymorphism is only in moderate LD with the hypertension-associated rs5963409 polymorphism (r 2 = 0.12). This prevented us from comparing our results with the Genome Wide Association study for hypertension. 29 Moreover, this unique Genome Wide Association study did not detect any genes previously associated with hypertension by candidate gene strategies. Several explanations have been proposed for this lack of association including a poor coverage of many genes by the Affymetrix chip used in this study and the absence of BP measurements in controls leading to a probable misclassification of some HT subjects as controls.
Although it cannot be ruled out that rs5963409 may be in LD with other yet unknown functional polymorphisms in the OTC locus or in other genes nearby, some data suggested that the rs5963409 minor allele may be of functional significance. Indeed, Bensemain et al. showed evidence for: (i) an overexpression of OTC in brain vascular endothelial cells from patients with Alzheimer's disease; (ii) a significant association of the rs5963409 minor allele with an increased risk of disease onset; (iii) a putative functional significance of the rs5963409 minor allele as it was shown to abolish methylation of a CpG island within the promoter of the OTC gene. 20 Given the close association between hypertension and Alzheimer's disease, 30 these results are consistent with this study. Nevertheless, it will be necessary to experimentally validate the functional role of the rs5963409 minor allele and to assess the putative effect of the six other SNPs that are in complete LD with the rs5963409 polymorphism.
In conclusion, our study showed that the rs5963409 polymorphism in the OTC gene was associated with both hypertension and a greater vasoconstriction in response to methylergonovine maleate. These associations reinforce the hypothesis according to which the urea metabolism may be linked to BP regulation. Our results provide a rationale for additional association studies in independent population samples and for investigation of the physiological mechanisms underlying the potential role for OTC in hypertension.
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